1月6日 - ** 药物开发商NovaBridgeNBP.O股价盘前上涨6.41%至4.65美元
** 该公司称，其实验性抗癌药物givastomig与标准化疗和免疫疗法一起用于晚期胃癌患者时，显示出良好的效果
** 公司称，对 54 名患者进行的研究显示，两种剂量的反应率分别为 77% 和 73
** NBP 称低剂量可延缓癌症进展近 17 个月；高剂量数据待定
** 该公司计划在今年年初进行全球试验，将药物与标准疗法进行比较 - NBP
** 截至上次收盘，该公司股价在过去一年中上涨了 ~10
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.